Emerging Clinical and Pre-Clinical Approaches to Oncolytics

Co-chairs: Balveen Kaur, PhD, and John Goldberg, MD

Register for Emerging Clinical and Pre-Clinical Approaches to Oncolytics

8:00 – 8:25 a.m.

Progress and Approval of G47delta
Tomoki Todo, PhD, Institute of Medical Science, University of Tokyo

8:25 – 8:50 a.m.

Development of Synthetic RNA Viral Immunotherapy
Lorena Lerner, PhD, Oncorus

8:50 – 9:15 a.m.

Drug Modulation of the Myeloid Tumor Microenvironment to Enable Oncolytic HSV Immunotherapy
Timothy Cripe, MD, PhD, Nationwide Children's Hospital

9:15 – 9:40 a.m.

Combinations of Early Trials
Howard Kaufman, MD, Harvard University

Break: 9:40 – 9:55 a.m.

9:55 – 10:20am

A Therapy Going Viral: Armed-Oncolytic Adenoviruses for the Treatment of Solid Tumors
Candelaria Gomez-Manzano, MD., MD Anderson Cancer Center

10:20 – 10:45 a.m.

An Oncolytic Herpes Virus Armed with a Full-length Anti-CD47 Antibody to Target “Don’t Eat Me” Signal and Fc Receptor-Mediated Antitumor Immunity
Jianhan Yu, PhD, City of Hope National Medical Center

10:45 – 11:10 a.m.

Bacterial Antigens Harnessed for Virotherapy
Evanthia Galanis, MD, DSc. Mayo Clinic

11:10 – 11:35 a.m.

Update in Clinical Trials of Oncolytic HSV for Brain Tumors
James Markert, MD, MPH, University of Alabama at Birmingham